Asset Details
Do you wish to reserve the book?
Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B
Do you wish to request the book?
Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B
2005
Overview
In the second phase of a randomized, placebo-controlled trial of adefovir dipivoxil for the treatment of hepatitis B e antigen (HBeAg)–negative chronic hepatitis B, patients who had been treated with adefovir during the initial 48 weeks of the trial were randomly assigned to be switched to placebo or to continue to receive adefovir. Patients who were switched to placebo lost the benefits that had been gained during the initial 48 weeks of treatment, and patients randomly assigned to continue adefovir therapy maintained a response. Resistance mutations developed in 6 percent of the patients treated with adefovir dipivoxil for 144 weeks.
Patients who were switched to placebo after 48 weeks lost the benefits that had been gained during initial treatment, and patients randomly assigned to continue adefovir therapy maintained a response.
An estimated 400 million people worldwide are chronically infected with hepatitis B virus (HBV). One million die each year from complications of infection, including cirrhosis, hepatocellular carcinoma, or both.
1
Hepatitis B e antigen (HBeAg)–negative chronic hepatitis B represents a late phase in the course of HBV infection.
2
Mutations in the precore promoter regions, core promoter regions, or both, which prevent the formation of HBeAg, are selected during or after HBeAg loss and seroconversion to antibody to HBeAg (anti-HBe). HBeAg-negative chronic hepatitis B infection is characterized by intermittent periods of exacerbation and quiescence. It frequently follows an aggressive disease course, with . . .
Publisher
Massachusetts Medical Society
Subject
Adenine - administration & dosage
/ Adenine - analogs & derivatives
/ Adult
/ Animals
/ Antiviral Agents - administration & dosage
/ Antiviral Agents - adverse effects
/ Antiviral Agents - therapeutic use
/ Biological and medical sciences
/ DNA
/ Drug Administration Schedule
/ Female
/ Hepatitis B e Antigens - blood
/ Hepatitis B virus - genetics
/ Hepatitis B virus - isolation & purification
/ Hepatitis B, Chronic - drug therapy
/ Humans
/ Male
/ Organophosphonates - administration & dosage
/ Organophosphonates - adverse effects
